Table 3.
Clinical characteristics of CBS sample
| Clinical characteristics | Frequency (%) at time of investigation (N =31) | Frequency (%) at follow-up (N =31) |
|---|---|---|
| Extrapyramidal features | ||
| Rigidity (asymmetric) | 28 (90.3%) | 31 (100%) |
| Dystonia | 16 (51.6%) | 18 (58.1%) |
| Levodopa trial with poor responsea | 13 (41.9%) | 13 (41.9%) |
| Tremor – postural/action | 8 (25.8%) | 11 (35.6%) |
| Cortical features | ||
| Apraxia | 28 (90.3%) | 31 (100%) |
| Cortical sensory loss | 19 (61.3%) | 19 (61.3%) |
| Alien-limb phenomenon | 1 (3.2%) | 3 (9.7%) |
| Limb levitation | 7 (22.6%) | 10 (32.3%) |
| Myoclonus | 9 (29.0%) | 13 (41.9%) |
| Early dementia | 22 (71.0%) | 22 (71.0%) |
| Language disturbance | 24 (77.4%) | 24 (77.4%) |
aThirteen patients had a trial of levodopa and all responded poorly based on clinical assessment. Average time for emergence of additional symptoms or signs on follow-up was 1.0 ± 0.3 years. CBS, corticobasal syndrome; N, number.